Brian S. Henick

NewYork–Presbyterian Hospital — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

23h-index3.7kcitations227works4.02yr avg

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Genomics and Diagnostics(72), Cancer Immunotherapy and Biomarkers(66), Lung Cancer Treatments and Mutations(29), Cancer Cells and Metastasis(24), Immunotherapy and Immune Responses(24)

Publications227 total

Hydrophobic complementarity-determining region 3 (CDR3) sequences elucidate the cardiotoxic effects of immune checkpoint inhibitors

2025Open Access

Table S5 from A Transcriptome-Based Precision Oncology Platform for Patient–Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies

2025Open Access

Key Resources Table from A Transcriptome-Based Precision Oncology Platform for Patient–Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies

2025Open Access

Table S4 from A Transcriptome-Based Precision Oncology Platform for Patient–Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies

2025Open Access

Table S3 from A Transcriptome-Based Precision Oncology Platform for Patient–Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies

2025Open Access

Table S7 from A Transcriptome-Based Precision Oncology Platform for Patient–Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies

2025Open Access

Table S8 from A Transcriptome-Based Precision Oncology Platform for Patient–Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies

2025Open Access

Table S1 from A Transcriptome-Based Precision Oncology Platform for Patient–Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies

2025Open Access

Table S2 from A Transcriptome-Based Precision Oncology Platform for Patient–Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies

2025Open Access

Supplementary Figures S1-S6 from A Transcriptome-Based Precision Oncology Platform for Patient–Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies

2025Open Access

Table S6 from A Transcriptome-Based Precision Oncology Platform for Patient–Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies

2025Open Access

Editorial: Nature and nurture in early onset lung cancer

Frontiers in Oncology·2025Open Access

Supplementary Figure 4 from Tumor-Derived CCL5 Recruits Cancer-Associated Fibroblasts and Promotes Tumor Cell Proliferation in Esophageal Squamous Cell Carcinoma

2025Open Access

Supplementary Figure 3 from Tumor-Derived CCL5 Recruits Cancer-Associated Fibroblasts and Promotes Tumor Cell Proliferation in Esophageal Squamous Cell Carcinoma

2025Open Access

Supplementary Figure Legends from Tumor-Derived CCL5 Recruits Cancer-Associated Fibroblasts and Promotes Tumor Cell Proliferation in Esophageal Squamous Cell Carcinoma

2025Open Access

Supplementary Figure 2 from Tumor-Derived CCL5 Recruits Cancer-Associated Fibroblasts and Promotes Tumor Cell Proliferation in Esophageal Squamous Cell Carcinoma

2025Open Access

Supplementary Figure 1 from Tumor-Derived CCL5 Recruits Cancer-Associated Fibroblasts and Promotes Tumor Cell Proliferation in Esophageal Squamous Cell Carcinoma

2025Open Access

Supplementary Data from Self-Renewing CD8<sup>+</sup> T-cell Abundance in Blood Associates with Response to Immunotherapy

2025Open Access

516 An open-label, phase II multicenter study of rituximab or tocilizumab for steroid-dependent or steroid-refractory immune-related adverse events due to immune checkpoint inhibitors

Regular and Young Investigator Award Abstracts·2025Open Access

1345 Initial phase 1a/1b results of STK-012, an α/β IL-2 receptor biased partial agonist, with pembrolizumab, pemetrexed, and carboplatin in 1L PD-L1 negative non-squamous NSCLC

2025Open Access

page 1 of 12Next →

Frequent Co-authors

Roy S. Herbst(10), Kurt A. Schalper(8), Naiyer A. Rizvi(7), David L. Rimm(6), Gary K. Schwartz(6), Justin F. Gainor(5), Matthew D. Hellmann(5), Mark M. Awad(5), Alexander I. Spira(5), Catherine A. Shu(5), Scott Gettinger(4), Desiree Schenk(4), David P. Carbone(4), Benny Johnson(4), Andrew R. Ferguson(4), Andrea Califano(4), Shoiab Bukhari(4), Robert Winchester(4), Benjamin Izar(4), Hiroshi Nakagawa(4)